Neurotech International Ltd has released a press release.
Neurotech Global Partnering and Registration Strategy
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Further Significant Improvement in Rett Syndrome Patients
- Phase II/III autism trial shows further benefits
- Significant improvement in Autism patients at 12 weeks
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
- Further clinical benefit at 52 weeks in PANDAS/PANS patients
Later from Neurotech International
- NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
- US FDA Response to Orphan Drug Request in PANDAS/PANS
- Neurotech Appoints Dr Anthony Filippis as MD/CEO
- Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
- NTI Receives Ethics Approval to Commence Human PK Study
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International